The INDEPENDENT peer review is at least several months out, according to Bernie at investor relations. More likely after the first of the year.
A positive INDEPENDENT peer review is something that could drive the price MUCH higher.
Dr. Kim's open market purchase was nice, and likely put a floor in PPS ($9, $2.25 pre R/S), but he's a biased player in the game, as should be obvious to ANYONE with a mind.
Again, a positive INDEPENDENT peer review is something that could drive the price MUCH higher, but it is not likely for months. The head of investor relations has said so. So it must be. That's the reality, folks.
I hate to burst your bubble, but the independent peer review will tell us whether to "load up."
Dr. Kim's purchase likely put a floor in the stock ($9, $2.25 pre R/S), but it proves nothing as he is a biased player in the game (for obvious reasons).
That said, I remain long and cautiously optimistic, pending the peer review of the data.
I agree detriever. A buyout offer would be the ONE catalyst which could overnight produce a share price of $50/share.
But any such offer is at least a year away, IMHO. There is a lot of data to vet and other trials to get started in the meantime, however.
I understand your point of view completely, too!
I believe that I'm going to do just that.
I have a friend who has lung cancer, and I am recommending that he become part of this clinical trial, if possible.
I'm long INO but also a realist.
Even in the best of all scenarios, we won't see $50/share for a couple of years. Now, don't get me wrong, that's still a helluva return from current levels.
But my point is that there is "plenty of time" to get shares while they are under $50. :)
Nonetheless, this is a VERY important trial, which I thought was to commence sometime in 2014.
No one seems to know anything about it's timeline anymore.
The one thing that many of us are looking forward to is the vetting of sub-group data.
That will help INO propose a P3 trial which has a much greater chance of success.
And who's to say that the treatment has to arbitrarily stop after a certain period of time, so long as the clearance percentage gets even better with more administrations over time.
We should know a LOT more by early next year!
Sac--we're not in disagreement here. This is still a highly manipulated stock.
My only point was that Dr. Kim didn't fully communicate all of the details that many of us were expecting during the CC. That's all; nothing more.
I couldn't agree more.
What percentage of the stock is still controlled by retail? By institutions?
Boy, you sure can't take it when someone doesn't preach your "party line."
Why don't you open yourself to some real objectivity once in awhile. Lest, you get cast as the ultimate p*****.
Many of us like contrarian views, as long as they have validity and potentially make sense. Investing is all about making balanced decisions, and such opinions (including yours) are always welcome, IMHO.
This is the one thing that is throwing some uncertainty into the company and stock.
Dr. Kim's purchase is great, but he has no control over the peer review, which hopefully is completely unbiased and objective.
And here's to hoping that it's timely and casts INO in a very impressive light!
Just because a certain amount of shares are "authorized" doesn't mean that they will ever be issued.
A more telling metric is "the shelf," which is an amount of money that a company can file for the issuance of shares against.
Dilution is always a concern with biotech start-ups, but I would not be worried at this point.
I've seen nothing about this trial over that last few weeks.
Is this P1 trial still due to be initiated in 2014? Aren't part of our milestone payments based on it's beginning?
This is the trial that MANY of us are most interested in, as the hTERT expression is found in 85% of all cancers and this could be part of a universal therapy for many of them.
Does ANYONE know anything about this VERY important trial? Is it still part of the INO pipeline?
By your analysis, a 10-year long who sells for a profit suddenly becomes a trader. I suppose you don't have any conception of what the "time value of money" means.
I will be holding far longer than just the end of the month, so it doesn't really matter whether I'm "up or down" at that point. The catalysts probably won't start to hit until September anyway. But in biotech, no one can predict exactly when they will hit. That's why you need to buy in perhaps a little early rather than to miss the boat entirely, as you have apparently done in life.
Do you consider yourself to be a pumper, a dumper, or just a lame#$%$ humpity-dumpty?
Oh, and by the way. Do you know what a catalyst is? It certainly isn't the first two parts of your alias rubbing against your pants leg. For the last part of your alias is probably as lame and as limp as they come.